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Abstract
Objectives. A study is made of the dental implications of oral cancer, with a view to avoiding the complications 
that appear once oncological treatment is started. 
Patients and Methods. The study comprised a total of 22 patients diagnosed with oral cancer according to clinical 
and histological criteria in the Service of Ma�illofacial Surgery (Dental Clinic of the University of Barcelona, 
Spain) during the period 1996-2005, and posteriorly treated in different hospital centers in Barcelona. 
Results. Of the 22 patients diagnosed with oral cancer in our Service, the present study finally analyzed the 12 
subjects who reported for the dental controls. As regards the remaining 10 patients, 5 had died and 5 could not 
be located; these subjects were thus e�cluded from the analysis. All of the smokers had abandoned the habit. The 
most common tumor location was the lateral margin of the tongue. None of the patients visited the dentist regu-
larly before the diagnosis of oral cancer. T1N0M0 was the most common tumor stage. Surgery was carried out 
in 50% of the cases, while 8.4% of the patients received radiotherapy and 41.6% underwent surgery with postop-
erative radiotherapy. In turn, 66.6% of the patients reported treatment sequelae such as dysgeusia, �erostomia or 
speech difficulties, and one patient suffered osteoradionecrosis. Forty-one percent of the patients did not undergo 
regular dental controls after cancer treatment. As regards oral and dental health, 16.6% presented caries, and 50% 
had active periodontal disease. 
Conclusions. Protocols are available for preventing the complications of oral cancer treatment, and thus for impro-
ving patient quality of life. However, important shortcomings in the application of such protocols on the part of 
the public health authorities make it difficult to reach these objectives.
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Introduction
Cancer incidence in humans has gradually increased 
over the last century. Surgical, radiotherapeutic, chemo-
therapeutic and biological treatments have e�perienced 
important advances, with an important reduction in the 
morbidity associated with the radical surgical practices 
of the past.
It is important to diagnose oral cancer in its early stag-
es, since the management of small and localized tumors 
(T1N0M0) involves less morbidity and mortality than 
more advanced-stage disease, where treatment must be 
more aggressive. Indeed, the stage in which the disease 
is diagnosed is directly correlated to long-term survival 
(1).
However, in practice many malignancies are diagnosed 
and treated in advanced stages and/or once the patients 
have already e�perienced symptoms causing them to 
seek medical help. This e�plains the great interest in 
improving multidisciplinary therapies, and particularly 
in establishing more reliable techniques for diagnosing 
head and neck tumors, with a view to securing detection 
in the early stages of the disease (2). 
The treatment of head and neck cancer is fundamentally 
based on surgery, radiotherapy, chemotherapy, biologi-
cal therapy, or any combination of such treatments. In 
turn, the management of malignant disease usually in-
volves to�ic effects upon healthy cells, and this can give 
rise to serious oral complications (3). 
Some of these complications can be significantly re-
duced by applying strict oral and dental controls and 
care before, during and after oncological treatment. The 
lack of a balanced diet, poor oral hygiene, the presence 
of fractured teeth or defective restorations, periodontal 
disease or poorly fitting dentures can contribute to the 
development of local or systemic infections which in 
turn may prevent the administration of complete antine-
oplastic therapy, requiring a reduction in dose or delay-
ing the application of therapy (3).
Ideally, oral e�amination should take place 2-4 weeks 
before the start of oncological treatment, to allow ade-
quate healing of any lesions caused by dental treatment. 
The dental surgeon must be aware of all the possible com-
plications of oral cancer treatment, and of the therapeutic 
options available to deal with them adequately (2,3).
The present study e�amines the dental implications in 
oral cancer patients, with a view to avoiding the com-
plications that appear once oncological treatment is 
started.
Patients and Methods
A retrospective observational study was made of the pa-
tients diagnosed with oral cancer according to clinical 
and histological criteria in the Service of Ma�illofacial 
Surgery (Dental Clinic of the University of Barcelona, 
Spain) during the period 1996-2005.
A total of  22 patients were documented, of which 10 
were e�cluded from the analysis (corresponding to 5 
deaths and 5 subjects that could not be located). The 
remaining 12 patients were seen again to collect data 
relating to the study variables.
The following variables corresponding to each patient 
were entered in a database: age, gender, to�ic habits be-
fore and after the diagnosis of oral cancer, lesion loca-
tion, histological findings and preoperative tumor stage, 
treatment provided and treatment sequelae, frequency 
of dental visits before cancer diagnosis and postopera-
tive dental controls – with the assessment of oral and 
dental health conditions at that time, including the pres-
ence of mucosal lesions, periodontal disease and dental 
caries (CPI and CAOD inde�es).
In all cases, oral cancer was diagnosed on the basis of 
the histological study of the lesions, followed by patient 
referral to the corresponding hospital center, where the 
required oncological treatment was provided.
The data were compiled by a single observer, and were 
processed using the SPSS version 12.0 statistical pack-
age (SPSS Inc., Chicago, USA) (license of the Univer-
sity of Barcelona, Spain). The Kolmogorov-Smirnov 
test with Lilliefors correction was used to assess nor-
mal distribution of the quantitative variables. Variables 
showing a normal distribution were reported as the 
mean and standard deviation (SD), while the median 
and interquartile range (IQR) were used in the absence 
of a normal distribution.
Results
The study analyzed a total of 12 patients (8 males (67%) 
and 4 females (33%) (Table 1). The mean patient age 
was 66.5 years (range 45-89). Fifty percent of the pa-
tients were smokers, and all of them stopped smoking 
after the diagnosis of oral cancer. In 6 cases (50%), the 
lesions were located on the lateral margin of the tongue, 
while three tumors were located in the floor of the mouth 
(25%), one in the palate (8.3%), one in the retromolar re-
gion (8.3%) and one in the lower lip (8.3%).
In the great majority of the cases the histological study 
revealed squamous cell carcinoma (11 patients, 91.6%), 
with the identification of adenocarcinoma in one patient 
(8.3%). Tumor stage at the time of the diagnosis was 
T1N0M0 in 8 cases (66.6%), TisN0M0 in three cases 
(25%), and T4N0M0 in a single patient (8.3%). Surgical 
resection was carried out in 6 cases (50%). Two patients 
received radiotherapy only (16.6%), while four were 
subjected to combination surgical resection plus radio-
therapy (33.3%). In two of these latter subjects graft-
based reconstructive surgery was carried out, since a 
hemimandibular resection had been performed in one 
case, and a hemima�illectomy in the other. 
A total of 6 subjects received radiotherapy either alone 
or in combination with surgery, and only one of these 
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subjects (16.6%) underwent dental treatment before ra-
diotherapy. A prosthesis was prepared in this case to 
protect the irradiated oral tissues, with the adoption of 
oral hygiene measures and conservative management of 
the dental caries.
None of the patients regularly visited the dentist for the 
routine control of oral and dental health during oncolog-
ical treatment. Dental visits were only recorded in the 
event of acute conditions in which the patients reported 
to the emergency service.
As regards patient follow-up after oncological treat-
ment, 8 subjects (67%) were controlled by their primary 
care dentist or private dentist and ma�illofacial surgeon, 
while the remaining four patients (33%) were seen only 
by the ma�illofacial surgeon.
The following treatment complications were recorded: 
speech difficulties in 5 cases (41.6%), xerostomia in four 
cases (33.3%)(though of milder intensity than at the start 
of oncological treatment), hypogeusia in three patients 
(25%), and osteoradionecrosis in one case (8.3%). This 
latter condition was successfully treated with antibiot-
ics, and the patient is presently asymptomatic.
As regards oral and dental health at the time of the con-
trol made during the study, 6 patients had active perio-
dontal disease (50%), and two presented caries (16.6%). 
Evaluation of the soft tissues in turn revealed reticular 
lichen planus in three patients (25%), diagnosed on the 
basis of the clinical and histological findings.
The mean time from the diagnosis of oral cancer to 
study data collection was 4.5 years (range 1-9 years).
Discussion
Oral and dental care in oral cancer patients should begin 
when the lesion is detected and the diagnosis is estab-
lished. Planning includes prior evaluation, patient prep-
aration, the measures to be applied after oncological 
treatment, and long-term follow-up. In our series, only 
one patient was referred to the general dentist for the 
prevention of oral complications of radiotherapy. How-
ever, after oncological treatment the number of patients 
controlled by the dentist was seen to increase (4).
The oral complications of radiotherapy or chemotherapy 
may manifest immediately or at a later stage in chronic 
form (5).
The potential immediate complications include mucosi-
tis. This is characterized by oral soft tissue inflamma-
tion, and is seen in 40% of all patients administered 
chemotherapy (6), and in 80-100% of those subjected 
to radiotherapy. Mucositis manifests as ulcerated and 
burning lesions between 7-10 days after the start of on-
Table 1. Study variables in the 12 patients evaluated.
Patient Location Histology Stage Treatment Treatment prior to oncological therapy 
Postoperative
dental control 
1 Lateral margin of the tongue 
Squamous cell 
carcinoma T1N0M0 Surgery No No 
2 Floor of the mouth
Squamous cell 
carcinoma T1N0M0
Surgery plus 
preoperative
radiotherapy 
No No 
3 Floor of the mouth
Squamous cell 
carcinoma T4N0M0
Surgery plus 
postperative 
radiotherapy 
No No 
4 Lateral margin of the tongue 
In situ 
carcinoma TisNOM0 Surgery No Yes 
5 Floor of the mouth
Squamous cell 
carcinoma T1N0M0 Surgery No No 
6 Lateral margin of the tongue 
Squamous cell 
carcinoma T1N0M0 Radiotherapy Yes Yes 
7
Lateral margin of 
the tongue 
Squamous cell 
carcinoma T1N0M0 Surgery No Yes 
8 Lower vestibular gums
In situ 
carcinoma TisNOM0
Surgery plus 
postperative 
radiotherapy 
No Yes 
9 Lateral margin of the tongue 
In situ 
carcinoma TisNOM0 Surgery No Yes 
10 Palate Adenocarci-noma T1N0M0
Surgery plus 
postperative 
radiotherapy 
No Yes 
11 Lower lip Squamous cell carcinoma T1N0M0 Radiotherapy No Yes 
12 Lateral margin of the tongue 
Squamous cell 
carcinoma T1N0M0 Surgery No Yes 
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cological treatment. While these lesions are transient, 
they greatly affect patient wellbeing – causing pain, 
burning sensation, dry oral mucosal membranes, over-
infections and difficulties for maintaining adequate oral 
hygiene or eating (7).
The treatment of mucositis is fundamentally preventive 
and palliative. The main objectives are to afford pain re-
lief and prevent the appearance of secondary infections. 
Many substances have been used to lessen the severity 
of mucositis. However, absolute efficacy has not been 
established for any of them. Such substances include 
the following: cytokines (granulocyte-macrophage 
colony-stimulating factor or GM-CSF), sucralfate, vita-
mins A and D, prostaglandins (PGE-1, PGE-2), immune 
modulators (immunoglobulins, indomethacin, pento�i-
fylline), amino acids (glutamine), cytoprotectors (ami-
nophosphine) and hormones (melatonin) (8). Lin et al. 
carried out a study to determine the effect of zinc upon 
mucositis. The authors concluded that the administra-
tion of zinc supplements in radiotherapy-based onco-
logical treatments can lessen the severity of mucositis 
and dermatitis (9).
In patients subjected to high-dose chemotherapy, other 
investigators have reported that prophyla�is based on 
oral rinses with GM-CSF does not lessen the severity 
of mucositis (10). At present, no method has received 
widespread acceptance for the prevention of mucositis 
(11). Pain control in mucositis can be achieved with topi-
cal local anesthetics, benzidamine, doxepin (12) or mor-
phine or other opioid drugs (13). Mucositis was not eval-
uated in our series, since data collection corresponded 
to late follow-up after initial oncological treatment.
Patients subjected to radiotherapy or chemotherapy may 
suffer neutropenia, which in turn increases the risk of 
serious infections. This complication requires antibiotic 
treatment for prolonged periods of time, thus potentially 
giving rise to alterations in oral flora and producing an 
environment favorable to the growth of opportunistic 
microorganisms. In this conte�t, 80% of all patients 
subjected to such treatments develop fungal infections, 
fundamentally produced by Candida albicans. The most 
common infections include viral agents such as Herpes 
simplex, Herpes zoster and Epstein-Barr virus. All of 
them give rise to clinical manifestations in the form of 
multiple ulcerations that cause eating difficulties. Such 
patients may also e�perience worsening or e�acerbation 
of periapical and periodontal bacterial infections that 
were already present before treatment, and which can 
lead to serious systemic complications. This e�plains 
the importance of ensuring the absence of oral and den-
tal infectious disease before starting oncological treat-
ment (14).
Alterations in salivary gland function are also frequent 
complications of radiotherapy. Such alterations are ob-
served in over 50% of all post-irradiation patients (15). 
In this conte�t, �erostomia produces dry mouth, burn-
ing sensation, changes in the tongue surface (depapil-
lation, reddening), cracked lips, eating difficulties and 
problems wearing dentures. Pathogenic modification of 
the oral flora can also occur, and the risk of dental caries 
increases (16). Xerostomia appears early from the sec-
ond week after the start of radiotherapy, and may prove 
irreversible (17). In our series, 33.3% of the irradiated 
patients e�perienced �erostomia, though to a lesser de-
gree than at the end of oncological treatment.
Symptomatic treatment of post-irradiation �erostomia 
in patients without residual salivary function is based 
on saliva substitutes such as carbo�ymethylcellulose, 
sorbitol, �ylitol, etc. (18). However, these products offer 
no significant beneficial effects, and many patients pre-
fer to swallow sips of water repeatedly as a lubricating 
measure (19). Patients with preserved residual salivary 
function can be treated with salivary stimulants such as 
pilocarpine, neostigmine, nicotinic acid, etc. (20). Fox et 
al., in a double-blind, placebo-controlled study of 39 pa-
tients with post-irradiation �erostomia, found 94.8% of 
the subjects to e�perience improvement after one month 
of treatment with 5 mg of pilocarpine three times a day 
– this improvement being maintained for 6 months after 
the end of radiotherapy (21). Many studies have shown 
that intensity-modulated radiotherapy contributes to 
improve salivary gland preservation (17,22-25).
Dysgeusia induced by radiotherapy is conditioned by 
a series of factors: direct neuroto�ic action upon the 
taste receptor cells, �erostomia and possible overinfec-
tions. Most patients recover within 2-3 months, though 
in some cases permanent hypogeusia may result (14). 
Twenty-five percent of our patients reported subjective 
permanently lessened taste sensation.
Thrombocytopenia and/or coagulation disorders in-
duced by chemotherapy can give rise to bleeding. Con-
sequently, in the presence of active periodontal disease 
during chemotherapy, the patient may bleed spontane-
ously, or hemorrhage may result from only minimal 
gingival trauma. Petechiae may also be observed, most 
often located on the lips, soft palate or floor of the mouth 
(8).
Late complications or the e�acerbation of acute condi-
tions may occur. These include particularly fibrosis and 
atrophy of the mucosal membranes, caries (typically 
rampant and very destructive) preferentially located 
in the region of the dental neck, dysgeusia and muscle 
fibrosis – giving rise to important limitations in man-
dibular movement (16). 
Osteoradionecrosis is the least frequent but also the 
most important late complication. It is characterized by 
aseptic necrosis of irradiated bone, with the loss of re-
generative capacity of the osteogenic tissue. The mucosa 
becomes friable and weak, thus favoring the appearance 
of lesions that fail to heal and which appear spontane-
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ously or secondary to only minor traumatisms. The di-
agnosis of osteoradionecrosis is based on the clinical 
manifestations such as ulceration or necrosis of the oral 
mucosa over a period of more than three months, to-
gether with the data provided by the panoramic X-ray 
study, which reveals irregular radiotransparencies with 
areas of abnormal radiopacity indicating the presence 
of bone sequestration. In our series only one patient 
with T1N0M0 cancer located in the floor of the mouth 
and subjected to radiotherapy before surgery developed 
osteoradionecrosis. This case was treated with analge-
sics and antibiotics, and the patient is presently free of 
symptoms.
We agree with other authors that the diagnosis and 
treatment of oral cancer requires a multidisciplinary ap-
proach, including the intervention of a dental surgeon. 
Unfortunately, most oncological teams do not contem-
plate the valuable contribution of the dentist in such pa-
tients. The oral cavity is often neglected in the evalua-
tion and planning of head and neck cancer therapy. As 
a result, no adequate measures are taken referred to the 
complications that may appear in any structure of the 
stomatognathic apparatus (14,16,26). This situation is 
particularly worrisome in pediatric oncological patients 
in which the late effects of cancer treatment upon den-
tal and ma�illary development are frequently not taken 
into account (27). 
Conclusion
Protocols for preventing the oral and dental complica-
tions of oral cancer treatment aim to improve patient 
quality of life. However, as has been seen in the present 
study, important shortcomings in the application of such 
protocols make it difficult to reach this objective.
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